Novel Role of Gestational Hydralazine in Limiting Maternal and Dietary Obesity-Related Chronic Kidney Disease.
DNA methylation
chronic kidney disease
fetal programming
maternal obesity
obesity
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
05
05
2021
accepted:
30
07
2021
entrez:
6
9
2021
pubmed:
7
9
2021
medline:
7
9
2021
Statut:
epublish
Résumé
Maternal obesity is a risk factor for chronic kidney disease (CKD) in offspring, underpinning the theory of the developmental origins of health and disease. DNA methylation has been implicated in the programming of adult chronic disease by maternal obesity, therefore, DNA demethylating agents may mitigate offspring risk of disease. In rodent models, low-dose hydralazine has previously been shown to reduce renal fibrosis via DNA demethylation. We used mouse models of maternal obesity and offspring obesity to determine whether administration of low-dose hydralazine during gestation can prevent fetal programming of CKD in offspring. Female C57BL/6 mice received high fat diet (HFD) or chow prior to mating, during gestation and lactation. During gestation, dams received subcutaneous hydralazine (5 mg/kg) or saline thrice-weekly. Male offspring weaned to HFD or chow, which continued until endpoint at 32 weeks. Biometric and metabolic parameters, renal global DNA methylation, renal functional and structural changes, and renal markers of fibrosis, inflammation and oxidative stress were assessed at endpoint. Offspring exposed to maternal obesity or diet-induced obesity had significantly increased renal global DNA methylation, together with other adverse renal effects including albuminuria, glomerulosclerosis, renal fibrosis, and oxidative stress. Offspring exposed to gestational hydralazine had significantly reduced renal global DNA methylation. In obese offspring of obese mothers, gestational hydralazine significantly decreased albuminuria, glomerulosclerosis, and serum creatinine. Obese offspring of hydralazine-treated lean mothers displayed reduced markers of renal fibrosis and oxidative stress. Gestational hydralazine decreased renal global DNA methylation and exerted renoprotective effects in offspring. This supports a potential therapeutic effect of hydralazine in preventing maternal obesity or dietary obesity-related CKD, through an epigenetic mechanism.
Sections du résumé
BACKGROUND
BACKGROUND
Maternal obesity is a risk factor for chronic kidney disease (CKD) in offspring, underpinning the theory of the developmental origins of health and disease. DNA methylation has been implicated in the programming of adult chronic disease by maternal obesity, therefore, DNA demethylating agents may mitigate offspring risk of disease. In rodent models, low-dose hydralazine has previously been shown to reduce renal fibrosis via DNA demethylation. We used mouse models of maternal obesity and offspring obesity to determine whether administration of low-dose hydralazine during gestation can prevent fetal programming of CKD in offspring.
METHODS
METHODS
Female C57BL/6 mice received high fat diet (HFD) or chow prior to mating, during gestation and lactation. During gestation, dams received subcutaneous hydralazine (5 mg/kg) or saline thrice-weekly. Male offspring weaned to HFD or chow, which continued until endpoint at 32 weeks. Biometric and metabolic parameters, renal global DNA methylation, renal functional and structural changes, and renal markers of fibrosis, inflammation and oxidative stress were assessed at endpoint.
RESULTS
RESULTS
Offspring exposed to maternal obesity or diet-induced obesity had significantly increased renal global DNA methylation, together with other adverse renal effects including albuminuria, glomerulosclerosis, renal fibrosis, and oxidative stress. Offspring exposed to gestational hydralazine had significantly reduced renal global DNA methylation. In obese offspring of obese mothers, gestational hydralazine significantly decreased albuminuria, glomerulosclerosis, and serum creatinine. Obese offspring of hydralazine-treated lean mothers displayed reduced markers of renal fibrosis and oxidative stress.
CONCLUSION
CONCLUSIONS
Gestational hydralazine decreased renal global DNA methylation and exerted renoprotective effects in offspring. This supports a potential therapeutic effect of hydralazine in preventing maternal obesity or dietary obesity-related CKD, through an epigenetic mechanism.
Identifiants
pubmed: 34485290
doi: 10.3389/fcell.2021.705263
pmc: PMC8416283
doi:
Types de publication
Journal Article
Langues
eng
Pagination
705263Informations de copyright
Copyright © 2021 Larkin, Nguyen, Hou, Glastras, Chen, Wang, Pollock and Saad.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Sci Rep. 2016 Mar 23;6:23525
pubmed: 27004609
Clin Epigenetics. 2013 Nov 19;5(1):21
pubmed: 24246027
Biochim Biophys Acta. 2013 Aug;1833(8):1979-84
pubmed: 23524114
Diabetologia. 2018 Apr;61(4):977-984
pubmed: 29185011
Nephrology (Carlton). 2012 May;17(4):311-21
pubmed: 22288610
Diabetes. 2002 May;51(5):1588-95
pubmed: 11978660
J Transl Med. 2006 Feb 28;4:10
pubmed: 16507100
J Am Soc Nephrol. 2006 Nov;17(11):2974-84
pubmed: 17035611
EBioMedicine. 2015 Jan;2(1):19-36
pubmed: 25717475
Nat Commun. 2015 Jul 03;6:7585
pubmed: 26139044
Biosci Rep. 2018 Mar 29;38(2):
pubmed: 29483369
Pediatr Res. 2007 May;61(5 Pt 2):68R-75R
pubmed: 17413843
Reprod Sci. 2014 Jan;21(1):131-7
pubmed: 23765376
Cardiovasc Res. 2009 Apr 1;82(1):9-20
pubmed: 19179352
Nutr Diabetes. 2018 Apr 25;8(1):18
pubmed: 29695710
PLoS One. 2017 Feb 22;12(2):e0172644
pubmed: 28225809
Am J Physiol Cell Physiol. 2016 Jan 1;310(1):C80-8
pubmed: 26491046
FASEB J. 2018 Oct;32(10):5215-5226
pubmed: 29688808
Diabetes. 2017 Mar;66(3):763-778
pubmed: 27899487
Int J Mol Sci. 2017 Feb 11;18(2):
pubmed: 28208659
Nature. 2013 Oct 24;502(7472):472-9
pubmed: 24153300
PLoS One. 2016 Aug 31;11(8):e0162131
pubmed: 27579698
Br J Clin Pharmacol. 2013 Oct;76(4):516-23
pubmed: 23441592
J Am Soc Nephrol. 2013 Nov;24(11):1756-68
pubmed: 23949798
Arthritis Rheum. 2003 Mar;48(3):746-56
pubmed: 12632429
Endocrinology. 2016 Nov;157(11):4104-4120
pubmed: 27571133
Hypertens Res. 2013 Sep;36(9):762-4
pubmed: 23842618
J Am Soc Nephrol. 2013 Nov;24(11):1709-11
pubmed: 23990672
Am J Cardiol. 2005 Oct 10;96(7B):25i-36i
pubmed: 16226933
Nutrients. 2018 Dec 21;11(1):
pubmed: 30577684
Nutr Metab Cardiovasc Dis. 2012 Dec;22(12):1067-74
pubmed: 21704502
Kidney Int. 2017 Jan;91(1):157-176
pubmed: 27692563
Free Radic Biol Med. 2011 Oct 1;51(7):1289-301
pubmed: 21777669
Am J Nephrol. 2017;45(3):283-291
pubmed: 28178697
Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1079-88
pubmed: 25887073
Adv Chronic Kidney Dis. 2013 Sep;20(5):390-5
pubmed: 23978543
J Am Soc Nephrol. 2013 Nov;24(11):1727-36
pubmed: 24115475
Pediatr Res. 2013 Apr;73(4 Pt 2):531-42
pubmed: 23314294
Int J Obes (Lond). 2013 Jan;37(1):140-5
pubmed: 22290534
Sci Rep. 2016 Jun 09;6:27769
pubmed: 27277011
Diabetologia. 2008 Apr;51(4):615-22
pubmed: 18270681
Elife. 2017 Nov 01;6:
pubmed: 29091029
Kidney Int. 2016 Jun;89(6):1221-30
pubmed: 27165817
J Physiol. 2016 Sep 1;594(17):4727-40
pubmed: 26970222
PLoS One. 2013;8(1):e54817
pubmed: 23382978
Autoimmunity. 2010 Feb;43(1):17-22
pubmed: 19961364
Obesity (Silver Spring). 2010 Feb;18(2):314-21
pubmed: 19680236
Antioxid Redox Signal. 2016 Jul 20;25(3):119-46
pubmed: 26906267
J Clin Invest. 1996 Sep 15;98(6):1465-70
pubmed: 8823313